We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reckitt Benckiser Group Plc | LSE:RB. | London | Ordinary Share | GB00B24CGK77 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6,498.00 | 6,502.00 | 6,506.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
06/2/2013 11:57 | It does seem time to take a few off the table. I guess the repetitive one must be about £8 a share down atm - hope that helps! | skinny | |
06/2/2013 11:50 | I think it's unjustifiably over the top on pricePerhaps we should sell some to spread risk out and get the alternative ULVRThat's got great news flow | stever4545 | |
05/2/2013 16:12 | This is becoming one whopping bubble!!!!!! Its an amazing rounded bubble. It s primed to pop. It should be a loud pop. Many pops have different loudness. I may not hear it, but Sheila tells me its one hell of a bubble, primed to pop. I have a £29.47 level 4 target, so thats where my buy orders are placed Hope it helps before the poppings | sanks | |
24/1/2013 12:19 | It's also available here (motionless) (bottom-left corner) | call-logger | |
24/1/2013 10:11 | Its here but its an aweful web site - the info is scrolling horizontally on the right, is unreadable, and locks up the computer. Best to do a 'save as' on the web page and then browse it with a text editor. | gbb483 | |
24/1/2013 08:44 | Key dates Full Year Results for 2012 13 February 2013 IMS - 22 April 2013 AGM - 2 May 2013 | call-logger | |
23/1/2013 21:51 | Hi. Anyone know when the next results are going to be ? | wildchild | |
17/1/2013 11:48 | Level 4 has it down as a massive nipplebusting bubble! Is it fair to say, £29 is a more likely drip drip Target? | sanks | |
16/1/2013 17:00 | 50 hope this helps | chevey | |
21/12/2012 16:00 | Just read a book. | brain smiley | |
20/12/2012 20:26 | It doesn't mean ought to me and Sheila and her fit mates!..we're just init to winnit! Looking for the bubble to pop...what unsustainable, remains so regardless of ramping rampoons doing the rounds! I have placed a reachable level 4 target of circa £29/£31 on this stock. My birds have been informed. Hope it helps Sanks....Wealth Transfer Specialist | sanks | |
05/12/2012 20:32 | APAD - past performance etc... | deepvalueinvestor | |
04/12/2012 22:45 | "Reckitt Benckiser's largest shareholder JAB Holdings to sell £1.3bn stake to fund Avon bid. The holding company, controlled by German billionaires the Reimanns, holds a 15.5pc stake in Reckitt. The sale was announced after the market closed, with 36m shares, about 4.9pc of the company, being offered at a price of £32.50 to £34." Lot of shares mopped up since then. From geswan:"Elephants don't gallop but if ever there was a galloping elephant its RB. Not just 2 or 3 years out but for ten years as well imho. Their brands are all household names, they have grown div, sales and EPS every year since 2000 (including 2008/9) and have a high margin. Share price since 2000 has over 400% growth (33% pa) with low volatility. Whats not to like with +3% yield?" apad | apad | |
04/12/2012 20:49 | Luckily I still had more to sell today! I wasn't expecting them to get quite this high although after breaking through £36, the chartists will continue to support until the fundamentals catch up. | deepvalueinvestor | |
03/12/2012 22:51 | Well done deepvalue...that is timing at its best, i must say :-)) Seen this many a times...relebtless bubbles poised for a dramatic drip drip BANG! ...expecting this to fall back into the £20's imo... Hope it helps | sanks | |
26/11/2012 22:44 | For those interested Spread Betting Magazine December edition is now online - it includes an interesting feature covering the major stock market crashes of the last 100 years | guidfarr | |
26/11/2012 21:55 | I agree Sanks. I had a big clear out on Friday after buying sub £30 in March 2011. Quality at any price? | deepvalueinvestor | |
26/11/2012 13:07 | I'm still waiting for £29 Its a bubble imo, not worth me putting me nob on the table. Sanks | sanks | |
08/11/2012 16:20 | Came across this on the Zulu thread: henryatkin 2 Nov'12 - 10:34 - 1322 of 1341 Simon42 ...Slater says elephants don't gallop but if ever there was a galloping elephant its RB. Not just 2 or 3 years out but for ten years as well imho. Their brands are all household names, they have grown div, sales and EPS every year since 2000 (including 2008/9) and have a high margin. Share price since 2000 has over 400% growth (33% pa) with low volatility. Whats not to like with +3% yield? Succinct comment. apad | apad | |
08/11/2012 12:37 | Sheila's target ranges from £27 to £30.17 The discrepancy is clear for every nob to see...just hope it doesn't hurt too much as the bubble starts to pop!! Hope the initial £29.87 level 4 target helps Sanks | sanks | |
25/10/2012 10:12 | Broker targets range from £35 to £42 | batman9 | |
24/10/2012 18:14 | a really excellent set of numbers, company really is on the firm path of more sustainable and higher quality growth | icf absolute | |
24/10/2012 16:16 | Reckitt Benckiser Group Plc (RB/) rose to a record in London trading after the maker of Nurofen posted revenue that beat estimates, defying a slowdown that has hurt competitors, boosted by increased sales of health-related products and a turnaround in developed markets. The shares gained as much as 6.2 percent to 3,858 pence, the highest price since the company was created by a merger in 1999. They were up 5.1 percent as of 2:34 p.m., extending the stock's gain for the year to about 20 percent. Non-pharmaceutical sales rose 5 percent on a comparable basis, the Slough, England-based company said today. The median estimate of 10 analysts surveyed by Bloomberg was for a 4 percent gain. The maker of Cillit Bang cleaners and Veet hair- removal creams also said it expects market growth this year to be at the top end of its forecast range and maintained a forecast that its sales will rise at a faster pace. "RB's like-for-like growth is strong and goes against the grain of most staple stocks, which are seeing a sales slowdown," Harold Thompson, an analyst at Deutsche Bank, said in a note to clients. Outdoing Rivals Chief Executive Officer Rakesh Kapoor has introduced new products like Durex Performax Intense condoms and boosted marketing spending to stem declines in slumping European markets while lifting sales in emerging regions such as Russia. Consumer-products makers including Nestle SA (NESN) and SABMiller Plc (SAB) last week reported sales growth in developing countries that missed estimates, raising concern of a slowdown in regions that the companies are relying on. Total sales declined 1 percent in the third quarter to 2.42 billion pounds ($3.87 billion). At constant exchange rates, revenue increased 4 percent, the company said. Reckitt Benckiser maintained a forecast (2F) for full-year sales growth in its non-pharmaceuticals businesses to be 2 percentage points ahead of the market. The growth of the market will be at the top end of the range of 1 percent to 2 percent that the company has seen this year, the company said. "We are doing better in a number of categories, and health-care has made a difference recently after being a drag in the first half of the year," Kapoor said in a phone interview. Sales of health-related brands such as Durex, Strepsils cold remedies and Gaviscon heartburn relief rose 7 percent, above the estimates of analysts such as Liberum Research's Pablo Zuanic. The company also kept its forecast for unchanged operating profit margins for the year. "We long disagreed with management's 1-2 percent market growth estimate, so we are somewhat pleased to see management slightly raising its estimate, even though we still find this new estimate to be prudent," Andrew Wood, an analyst at Sanford C. Bernstein, said in a note to clients today. 'Mood Music' Like-for-like revenue rose 2 percent in Europe and North America, which make up more than half of total revenue and are reported as one unit. That's an improvement compared with a 1 percent drop for the first six months of the year. Danone (BN), the world's biggest yogurt maker, last week said declines in Spain and Greece caused the weakest growth in sales of dairy products in more than three years. "Europe was surprising to me," Martin Deboo, an analyst at Investec, said in an interview. "Generally, the mood music is that Europe in particular is not changing. Yet Reckitt is exceeding expectations and moving into growth." Kapoor said that conditions in southern Europe have "gone from worse to bad," and increased marketing spending has "probably started to bear fruit." To lift sales, Reckitt Benckiser is investing an additional 100 million pounds in main brands such as Harpic cleaners, and shifting more of its marketing spending from television ads to digital media and consumer education campaigns. Durex, Veet Revenue increased 11 percent in Latin America and Asia, fueled by brands such as Durex condoms, Dettol cleaners and Finish dishwashing detergent. Sales rose 7 percent in Russia, the Middle East and Africa, helped by consumers buying more Durex, Veet and Gaviscon. Revenue at the pharmaceuticals division, which Reckitt Benckiser considers a "non-core" activity, rose 6 percent. The company said last month it will cease production of the Suboxone opioid-dependency drug in tablet form within six months as it weans patients onto a film-strip version that's less likely to be taken accidentally by children. Reckitt Benckiser said the film version of Suboxone that dissolves under the tongue has now captured a 60 percent volume share in the U.S., up from 48 percent at the end of 2011. "The number of patients on the tablet is shrinking," Kapoor said. "Six months from now, a vast percentage would have been on the film anyway." To contact the reporter on this story: Matthew Boyle in London at mboyle20@bloomberg.n To contact the editor responsible for this story: Celeste Perri at cperri@bloomberg.net | batman9 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions